Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

EarningsMounjaroZepboundPositive

AI Analysis

Summary

Eli Lilly reported Q2 2026 results with 48% revenue growth to $23.0 billion driven by Mounjaro and Zepbound, and raised full-year guidance. The company achieved 26-33% EPS growth with continued pipeline progress.

Financial Highlights

Revenue

$23.0 billion

EPS

$7.94 reported basis, $8.38 non-GAAP basis

Guidance

raised full-year guidance

Importance:6/10

Sentiment:

0.80

earningsrevenue growthguidance raiseMounjaroZepboundpipeline progress

Related Companies

$LLY

Read the original article

Published by PR Newswire Pharma on August 5, 2026 10:45 AM

Read Original